Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity

Blood

Volumn 123, Issue 12, 2014, Pages 1957-1960

  Kohrt, Holbrook E ^a   Sagiv Barfi, Idit ^a   Rafiq, Sarwish ^b   Herman, Sarah E M ^b   Butchar, Jonathon P ^b   Cheney, Carolyn ^b   Zhang, Xiaoli ^c   Buggy, Joseph J ^d   Muthusamy, Natarajan ^b   Levy, Ronald ^a   Johnson, Amy J ^b,c   Byrd, John C ^b,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d PHARMACYCLICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRUTON TYROSINE KINASE; CD20 ANTIGEN; CHROMIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; IBRUTINIB; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN TYROSINE KINASE; RITUXIMAB; TRASTUZUMAB;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CELL LINE; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE; DEGRANULATION; DOSE RESPONSE; DRUG ANTAGONISM; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LETTER; LYMPHOMA CELL; MONOTHERAPY; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE; CELL LINE, TUMOR; DRUG INTERACTIONS; HUMANS; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; MICE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES;

EID: 84897563710     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-547869     Document Type: Letter

References (6)

1. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507-516.
2. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
3. Khurana D, Arneson LN, Schoon RA, Dick CJ, Leibson PJ. Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk. J Immunol. 2007;178(6):3575-3582. (Pubitemid 46417624)
4. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104(9):2635-2642. (Pubitemid 39434941)
5. Kohrt HE, Houot R, Goldstein MJ, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432.
6. Di Paolo JA, Huang T, Balazs M, et al. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol. 2011;7(1):41-50.